Go Pro

Werewolf Therapeutics (HOWL) 10K Form and Latest SEC Filings 2026

Werewolf Therapeutics logo
$0.40 +0.02 (+4.84%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+0.07%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Werewolf Therapeutics SEC Filings & Recent Activity

Werewolf Therapeutics (NASDAQ:HOWL) has submitted 362+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Werewolf Therapeutics's financial statements. The most recent filing was a Form 10-Q submitted on July 31, 2026.

Form 4
Werewolf Therapeutics, Inc. Reports Ownership Change on Jul. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Werewolf Therapeutics Files Current Report on Jul. 31, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Werewolf Therapeutics Files Quarterly Report on Jul. 31, 2026

The 10-Q contains Werewolf Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Werewolf Therapeutics SEC Filing History

Browse Werewolf Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/31/2026 6:10 AM
Werewolf Therapeutics (1785530) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2026 6:06 AM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2026 4:34 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/06/2026 4:18 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:18 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:18 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/02/2026 7:26 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/29/2026 6:07 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2026 4:29 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:30 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:30 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 4:39 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/22/2026 5:59 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2026 6:02 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/16/2026 5:01 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2026 7:16 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/11/2026 7:13 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2026 4:20 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:13 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2026 5:42 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2026 5:51 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2026 4:02 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:04 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/26/2026 5:18 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2026 5:08 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 4:01 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:01 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:03 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Ray Dalio: Buy Gold. Get Paid. (Ad)

Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and crypto as U.S. debt continues to climb and fiat currencies lose purchasing power. A little-known $15 fund is already converting gold's momentum into monthly income - as much as $1,152 per month. No gold bars, no mining stocks, just consistent payouts.tc pixel

See how to follow Dalio's gold strategy and collect monthly income
05/14/2026 4:23 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/13/2026 3:06 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 6:56 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/12/2026 6:47 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 5:26 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 3:31 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:33 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:33 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2026 5:22 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 6:04 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/04/2026 5:00 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:52 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:52 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:52 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 6:16 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2026 3:47 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:47 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:47 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:59 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:01 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:01 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2026 6:07 AM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2026 6:12 AM
Werewolf Therapeutics (1785530) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/24/2026 4:26 PM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/11/2026 2:46 PM
Longwood Fund III, L.P. (1640546) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13G/A
02/06/2026 3:41 PM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2026 3:07 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 4:36 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
01/15/2026 4:22 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:09 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 4:12 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:58 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:59 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:54 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:54 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:56 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:57 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 4:32 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad)

In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.tc pixel

See Jim Rickards' full market warning and what it means for your portfolio
12/29/2025 5:59 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
12/29/2025 4:27 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:45 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:45 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:46 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:47 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:47 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:48 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2025 3:55 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Werewolf Therapeutics SEC Filings - Frequently Asked Questions

Werewolf Therapeutics (HOWL) has submitted 362+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Werewolf Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Werewolf Therapeutics's financial statements page.

The most recent filing was a Form 10-Q submitted on July 31, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:HOWL) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners